Abstract:PROteolysis TArgeting Chimeras (PROTACs) have been considered the next blockbuster therapies. However, due to their inherent limitations, the efficacy of PROTACs is frequently impaired by limited tissue penetration and particularly insufficient cellular internalization into their action sites. Herein, based on the ultra-pH-sensitive and enzyme-sensitive nanotechnology, a type of polymer PROTAC conjugated and pH/cathepsin B sequential responsive nanoparticles (PSRNs) are deliberately designed, following the construction of the PROTAC for Cyclin-dependent kinase 4 and 6 (CDK4/6). Colorectal cancer (CRC) which hardly responds to many treatments even immune checkpoint blockades was selected as the tumor model in this study. As a result, PSRNs were found to maintain nanostructure (40 nm) in circulation and efficiently accumulated in tumors via enhanced permeation and retention effect. Then, they were dissociated into unimers (<10 nm) in response to an acidic tumor microenvironment, facilitating tumor penetration and cellular internalization. Eventually, the CDK4/6 degrading PROTACs were released intracellularly following the cleavage of cathepsin B. Importantly, PSRNs led to the enhanced degradation of target protein in vitro and in vivo. The degradation of CDK4/6 also augmented the efficacy of immune checkpoint blockades, through the upregulation of programmed cell death-ligand 1 (PD-L1) expression in cancer cells and the suppression of regulatory T cells cell proliferation in tumor microenvironment. By combination with α-PD-1, an enhanced anti-tumor outcome is well achieved in CT26 tumor model. Overall, our study verifies the significance of precise intracellular delivery of PROTACs and introduces a promising therapeutic strategy for the targeted combination treatment of CRC.

Enhanced Tumor Targeting and Penetration of Proteolysis-Targeting Chimeras Through Irgd Peptide Conjugation: A Strategy for Precise Protein Degradation in Breast Cancer.

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Aptamer-PROTAC Conjugates (APCs) for Tumor-specific Targeting in Breast Cancer.

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors

Proteolysis targeting chimera extracellular vesicles for therapeutic development treating triple negative breast cancer

Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future

[Advances in targeted delivery of proteolysis targeting chimeras in cancer therapy]

A region-confined PROTAC nanoplatform for spatiotemporally tunable protein degradation and enhanced cancer therapy

Sequential responsive nano-PROTACs for precise intracellular delivery and enhanced degradation efficacy in colorectal cancer therapy

Discovery of novel penetrating peptides able to target human leukemia and lymphoma for enhanced PROTAC delivery

Proteolysis-targeting chimeras (PROTACs) in cancer therapy

Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy

Targeted delivery of PROTAC-based prodrug activated by bond-cleavage bioorthogonal chemistry for microneedle-assisted cancer therapy

A PROTAC Augmenter for Photo‐driven Pyroptosis in Breast Cancer

Stimuli-activatable PROTACs for precise protein degradation and cancer therapy

A Self-Assembled Affibody-Protac Conjugate Nanomedicine for Targeted Cancer Therapy

ClickRNA-PROTAC for Tumor-Selective Protein Degradation and Targeted Cancer Therapy